Program delivered on smartphone is based on core principles of cognitive behavioral therapy, with focus on behavioral activation.
Trial results demonstrate clinically meaningful reduction in depression symptoms.
Completing SparkRx as recommended results in statistically significant reduction in symptoms compared to control
Limbix announced on Friday the launch of SparkRx, which it says is the first evidence-based digital therapeutic (DTx) for adolescents and young adults aged 13 to 22 with symptoms of depression. The programme, which is delivered on a smartphone, is based on the core principles of cognitive behavioural therapy, with a focus on behavioural activation.
Benjamin Alouf, M.D., chief medical officer of Limbix, will present clinical data demonstrating the efficacy of SparkRx in adolescents with moderate to severe depressive symptoms at the upcoming American Academy of Pediatrics (AAP) National Conference. The virtual conference begins Oct. 8.
Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced the appointment of Jessica Lake, Ph.D., as chief science officer and Aarthi Padmanabhan, Ph.D., as chief research officer.
Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced that Benjamin Alouf, M.D., has been named chief medical officer. Dr. Alouf is a board-certified pediatrician with more than two decades of experience overseeing and executing clinical programs and policies.
When the pandemic began more than a year ago, the country changed overnight. For teens everywhere, there were a lot of unexpected adjustments -- schools closed, extracurricular activities were non-existent and friendships were reduced to Zoom hangouts and virtual TikTok challenges.
Dr. Gold is a pediatric psychologist and full professor at USC Keck School of Medicine and has been working with teens and children for over 30 years.
The INVEST Digital Health Virtual conference Pitch Perfect competition, from September 21-25, had some intense competition between the healthcare startup participants. Thanks to all the entrepreneurs, judges and sponsors who took part.
The new funding enables further research and development of the company’s flagship product, Limbix Spark, the first prescription digital therapeutic designed to treat adolescents with depression.
May 6, 2020
For media inquiries and our press kit, please contact email@example.com